Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.00 | 23.70 | -0.27% |
| CAC 40 | 7,741.07 | 34.83 | -0.45% |
| DAX 40 | 23,714.20 | 234.70 | -0.98% |
| Dow JONES (US) | 42,865.77 | 1.10 | -0.00% |
| FTSE 100 | 8,859.11 | 5.24 | -0.06% |
| HKSE | 24,035.38 | 331.56 | -1.36% |
| NASDAQ | 19,615.88 | 99.11 | -0.50% |
| Nikkei 225 | 38,173.09 | 248.10 | -0.65% |
| NZX 50 Index | 12,649.10 | 43.17 | 0.34% |
| S&P 500 | 6,022.24 | 16.57 | -0.27% |
| S&P/ASX 200 | 8,565.10 | 27.00 | -0.31% |
| SSE Composite Index | 3,402.66 | 0.34 | 0.01% |